Señalización PI3K / Akt / mTOR
Los inhibidores de la señalización PI3K/Akt/mTOR son compuestos que se dirigen a las vías de la fosfoinositida 3-cinasa (PI3K), la cinasa Akt y el blanco de la rapamicina en mamíferos (mTOR). Estas vías son reguladores críticos del crecimiento celular, la supervivencia, el metabolismo y la autofagia, lo que las convierte en objetivos clave en la investigación del cáncer y los trastornos metabólicos. Inhibir estas vías puede ayudar a controlar el crecimiento y la proliferación tumoral, ofreciendo potenciales estrategias terapéuticas para varios tipos de cáncer y otras enfermedades caracterizadas por una señalización celular desregulada. En CymitQuimica, ofrecemos una amplia selección de inhibidores de alta calidad de PI3K/Akt/mTOR para apoyar su investigación en oncología, señalización celular y enfermedades metabólicas.
Subcategorías de "Señalización PI3K / Akt / mTOR"
- AMPK(158 productos)
- ATM / ATR(71 productos)
- ADN-PK(51 productos)
- EGFR(572 productos)
- MELK(7 productos)
- PDK(9 productos)
- PI3K(242 productos)
- Quinasa S6(9 productos)
- gsk-3(112 productos)
- mTOR(144 productos)
Mostrar 2 subcategorías más
Se han encontrado 1038 productos de "Señalización PI3K / Akt / mTOR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
NVP-BBD130
CAS:<p>NVP-BBD130 is a stable, ATP-competitive, potent, orally active inhibitor of PI3K and mTOR.</p>Fórmula:C28H21N5OForma y color:SolidPeso molecular:443.5EGFR/HER2-IN-3
CAS:<p>EGFR/HER2-IN-3 (Compound ZINC21942954) is a dual EGFR and HER2 inhibitor.</p>Fórmula:C26H23N5O3Forma y color:SolidPeso molecular:453.49DNA-PK-IN-7
CAS:<p>DNA-PK-IN-7 is a potent DNA-PK inhibitor (IC50= 1 nM) (WO2021104277A1, compound 5).</p>Fórmula:C19H21N9O2Forma y color:SolidPeso molecular:407.43eCF-309
CAS:<p>eCF-309 is a potent mTOR inhibitor with IC50 value of 15 nM.</p>Fórmula:C18H21N7O3Forma y color:SolidPeso molecular:383.4EGFR-IN-31
CAS:<p>EGFR-IN-31: Potent EGFR inhibitor, targets mutations & overexpression in NSCLC; potential cancer research compound. (WO2021185298A1, 2)</p>Fórmula:C32H36FN7O2Forma y color:SolidPeso molecular:569.67PDZ1i
CAS:<p>PDZ1i: potent MDA-9/Syntenin inhibitor; crosses blood-brain barrier; targets GBM, FAK, EGFRvIII; lowers MMP secretion.</p>Fórmula:C28H26N8O4Forma y color:SolidPeso molecular:538.56BIBX 1382 Dihydrochloride
CAS:<p>BIBX 1382 Dihydrochloride blocks Lassa/Ebola entry, aids in studying virus-host interactions, and hints at kinase targets for therapy.</p>Fórmula:C18H21Cl3FN7Forma y color:SolidPeso molecular:460.76LDC0496
CAS:<p>LDC0496: Potent EGFR/Her2 exon 20 inhibitor; selective for wild-type EGFR, kinase-specific.</p>Fórmula:C32H35N5O3Forma y color:SolidPeso molecular:537.65EGFR-IN-69
CAS:<p>EGFR-IN-69: Potent EGFR inhibitor for NSCLC research; IC50: 4.3-25.6 nM against various EGFR mutations.</p>Fórmula:C31H37Cl2N7O3SForma y color:SolidPeso molecular:658.64PfGSK3/PfPK6-IN-2
CAS:<p>PfGSK3/PfPK6-IN-2 inhibits Plasmodium falciparum GSK3/PK6 (IC50: 172 nM/11 nM) for Malaria research.</p>Fórmula:C24H25Cl2N5OSForma y color:SolidPeso molecular:502.46EGFR-IN-63
CAS:<p>EGFR- IN-63 is an EGFR inhibitor with an IC50 value of 0.096 μM. EGFR- IN-63 exhibited anticancer effects on MCF-7 cells (IC50: 2.49 μM).</p>Fórmula:C20H12BrN5SForma y color:SolidPeso molecular:434.31PI3Kδ-IN-3
CAS:<p>PI3Kδ-IN-3 (TC KHNS 11) is a PI3Kδ inhibitor with an IC50 value of 9 nM.PI3Kδ-IN-3 has a favorable pharmacokinetic profile and inhibits B cell function.</p>Fórmula:C28H24N6O3Pureza:98.43%Forma y color:SolidPeso molecular:492.53EMI48
CAS:<p>EMI48, a derivative of EMI1, exhibits increased efficacy against mutant EGFR compared to EMI1. It specifically inhibits EGFR triple mutants [1].</p>Fórmula:C21H20N2O3Forma y color:SolidPeso molecular:348.4OXA-01
CAS:<p>OXA-01 is a potent mTORC1 and mTORC2 inhibitor, with IC 50 values of 29 nM and 7 nM, respectively [1]. OXA-01 demonstrates broad anti-tumor activity.</p>Fórmula:C21H20ClN5O2Forma y color:SolidPeso molecular:409.87BRD1652
CAS:<p>BRD1652 is a highly selective and potent GSK3 inhibitor.</p>Fórmula:C20H20F3N3OPureza:98%Forma y color:SolidPeso molecular:375.39CC260
CAS:<p>CC260 selectively inhibits PI5P4Kα/β (Ki: 40/30 nM), with minimal effect on Plk1/RSK2, useful for metabolic, diabetes, and cancer studies.</p>Fórmula:C24H29Cl2N5O2Forma y color:SolidPeso molecular:490.43AS2541019
CAS:<p>AS2541019 is a selective Phosphatidylinositol-3-kinase p110δ (PI3Kδ) inhibitor.</p>Fórmula:C26H33F2N7O3Forma y color:SolidPeso molecular:529.58CHMFL-PI4K-127
CAS:<p>CHMFL-PI4K-127 (15g) selectively inhibits PfPI4K (IC50=0.9 nM), potent against Plasmodium 3D7 (EC50=25.1 nM), with oral anti-malaria activity.</p>Fórmula:C18H15ClN4O3SForma y color:SolidPeso molecular:402.85EGFR-IN-54
CAS:<p>EGFR-IN-54 (Compound 3c) is a potent inhibitor of EGFR (IC50: 1.623 μM) and is toxic to cancer cells.</p>Fórmula:C17H14N4O4S3Forma y color:SolidPeso molecular:434.51EGFR-IN-25
CAS:<p>EGFR-IN-25, an efficacious EGFR inhibitor, demonstrates IC50 values of 9 nM for BaF3 cells (EGFR DEL19/T790M/C797S) and 60 nM for A431 cells (WT), respectively.</p>Fórmula:C34H43N9O2Forma y color:SolidPeso molecular:609.76EMI56
CAS:<p>EMI56, a derivative of EMI1, exhibits enhanced potency against mutant EGFR compared to EMI1. Additionally, EMI56 effectively inhibits EGFR triple mutants[1].</p>Fórmula:C21H20N2O3Forma y color:SolidPeso molecular:348.4EGFR-IN-39
CAS:<p>EGFR-IN-39, an acrylamide, is a potent EGFR inhibitor and antitumor agent targeting NSCLC with low toxicity. See WO2021185348A1 for details.</p>Fórmula:C24H25ClN6O3Forma y color:SolidPeso molecular:480.95JBJ-09-063 hydrochloride
<p>JBJ-09-063 hydrochloride: targeted EGFR inhibitor, effective for various mutations and TKI-resistant lung cancer models.</p>Fórmula:C31H30ClFN4O3SForma y color:SolidPeso molecular:593.11EGFR/HER2-IN-2
CAS:<p>EGFR/HER2-IN-2 (Compound ZINC35560729) is a dual EGFR and HER2 inhibitor that acts on both EGFR (IC50: 5.02 μM) and HER2 (IC50: 0.83 μM).</p>Fórmula:C26H23N5O3Forma y color:SolidPeso molecular:453.49SIC-19
CAS:<p>SIC-19, a SIK2 inhibitor, functions by promoting the degradation of SIK2 protein via the ubiquitination pathway. It inhibits the growth of cancer cells and sensitizes cells, ovarian cancer organoids, and xenograft models to PARP inhibitors (such as Olaparib).</p>Fórmula:C29H26N4O5S2Forma y color:SolidPeso molecular:574.67EGFR-IN-21
CAS:<p>EGFR-IN-21, a potent EGFR inhibitor, exhibits an IC50 of 0.38 nM, demonstrating significant antitumor activity.</p>Fórmula:C36H44BrN10O2PForma y color:SolidPeso molecular:759.68PI3Ka-IN-5
CAS:<p>PI3Ka-IN-5 is a potent PI3Kα/mTOR inhibitor, with an IC 50 of 0.7 nM and 3.3 nM, respectively. PI3Ka-IN-5 can be used for the research of colorectal cancer .</p>Fórmula:C30H35N9O5Forma y color:SolidPeso molecular:601.66EGFR mutant-IN-2
CAS:<p>EGFR mutant-IN-2 (Compound D51) is an inhibitor of EGFR mutants, specifically targeting EGFR L858R/T790M/C797S and EGFR del19/T790M/C797S mutants with IC50 values of 14 nM and 62 nM, respectively. This compound exhibits favorable pharmacokinetic (PK) parameters, safety properties, in vivo stability, and demonstrates antitumor activity [1].</p>Fórmula:C27H27F3N6O2SForma y color:SolidPeso molecular:556.6ON 146040
CAS:<p>ON 146040 is an effective inhibitor of PI3K isoforms with IC50s of 14 and 20 nM for PI3Kα and PI3Kδ, respectively.</p>Fórmula:C24H23N7O3SPureza:97.39%Forma y color:SolidPeso molecular:489.55P-2281
CAS:<p>P-2281 is an mTOR inhibitor with anticancer and anti-inflammatory properties.P-2281 inhibits dextran sulfate sodium (DSS)-induced colitis by suppressing T-cell</p>Fórmula:C9H8ClN3OPureza:99.95%Forma y color:SolidPeso molecular:209.63PI3K/mTOR Inhibitor-13
CAS:<p>PI3K/mTOR Inhibitor-13, an oral dual blocker of PI3K and mTOR, may treat sexual diseases, solid tumors, and IPF.</p>Fórmula:C20H13F2N5O3SForma y color:SolidPeso molecular:441.41PI3Kα/mTOR-IN-1
CAS:<p>PI3Kα/mTOR-IN-1 is a potent dual inhibitor of PI3Kα/mTOR.</p>Fórmula:C16H18N6OPureza:99.89%Forma y color:SolidPeso molecular:310.35EGFR-IN-2
CAS:<p>EGFR-IN-2 is a oral and mutation-selective EGFR inhibito,NSCLC, with high selectivity for resistant single and double mutant T790M.</p>Fórmula:C26H33N9O3SPureza:98.52% - 99.79%Forma y color:SolidPeso molecular:551.66Mutated EGFR-IN-2
CAS:<p>Mutated EGFR-IN-2 is an inhibitor of mutant-selective EGFR.</p>Fórmula:C29H35FN8O3Pureza:98%Forma y color:SolidPeso molecular:562.64PI3K/mTOR Inhibitor-8
CAS:<p>PI3K/mTOR Inhibitor-8: Dual PI3Kα (IC50: 0.46 nM) & mTOR (IC50: 12 nM) inhibitor; blocks G1/S phase & induces apoptosis in HCT-116 cells.</p>Fórmula:C23H22N8O4SForma y color:SolidPeso molecular:506.54PI3K-IN-38
CAS:<p>PI3K-IN-38: oral PI3K inhibitor, IC50 of 0.541 µM, anticancer, anti-inflammatory, halts tumors in vivo.</p>Fórmula:C20H24N6O2Pureza:99.89%Forma y color:SolidPeso molecular:380.44AMPK activator 4
CAS:<p>Potent, selective AMPK activator 4 enhances glucose tolerance and insulin sensitivity without affecting mitochondrial complex I.</p>Fórmula:C24H21ClN2O3Pureza:99.46% - 99.65%Forma y color:SolidPeso molecular:420.89Tyrphostin AG 112
CAS:<p>Tyrphostin AG 112 is an inhibitor of EGFR phosphorylation.</p>Fórmula:C13H8N4OPureza:97.01%Forma y color:SolidPeso molecular:236.23PI3K-IN-9
CAS:<p>PI3K-IN-9 is a potent and selective inhibitor of PI3Kδ(IC50 of 8.9 nM).</p>Fórmula:C19H23N7OPureza:98%Forma y color:SolidPeso molecular:365.43EGFR-IN-53
CAS:<p>EGFR-IN-53 (Compound 7) is a potent inhibitor of EGFR (IC50 = 8.264 μM) that exhibits cytotoxic activity against cancer cell lines [1].</p>Fórmula:C14H13N3O2SForma y color:SolidPeso molecular:287.34PI3K-IN-10
CAS:<p>PI3K-IN-10 is a potent inhibitor of pan-PI3K .</p>Fórmula:C23H19ClN6OPureza:98%Forma y color:SolidPeso molecular:430.89PI3Kγ inhibitor 1
CAS:<p>PI3Kγ inhibitor 1 is a inhibitor of PI3Kδ and PI3Kγ.</p>Fórmula:C32H26N8O2SPureza:98%Forma y color:SolidPeso molecular:586.67EGFR/C797S-IN-1
CAS:<p>EGFR/C797S-IN-1: Potent EGFR-C797S inhibitor, IC50 of 0.128 µM, dose-dependent p-EGFR suppression, anti-tumor properties.</p>Fórmula:C28H30N4O3Forma y color:SolidPeso molecular:470.56PI3-Kinase α Inhibitor 2
CAS:<p>Phosphatidylinositol 3-kinase (PI3K) catalyzes the phosphorylation of the 3' hydroxyl position of PIs to produce the second messengers PtdIns-(3,4)-P2 and</p>Fórmula:C16H15N3O2SForma y color:SolidPeso molecular:313.37EGFR-IN-5
CAS:<p>EGFR-IN-5 inhibits EGFR & mutants; IC50: EGFR 10.4nM, L858R 1.1nM, L858R/T790M 34nM, L858R/T790M/C797S 7.2nM.</p>Fórmula:C31H38FN9OPureza:98.17%Forma y color:SolidPeso molecular:571.69PI3Kδ/γ-IN-1
CAS:<p>PI3Kδ/γ-IN-1 is a selective and effective inhibitor of PI3Kδ/γ that can be used in the treatment of hematologic malignancies.</p>Fórmula:C25H28N6O4SForma y color:SolidPeso molecular:508.59PP30
CAS:<p>PP30 is an inhibitor of mTORC1 and mTORC2. It is selective within the PI3K family, inhibiting other PI3Ks only at high concentrations.</p>Fórmula:C18H19N7OSPureza:98%Forma y color:SolidPeso molecular:381.45PI3K/mTOR Inhibitor-3
CAS:<p>PI3K/mTOR Inhibitor-3, a potent dual-action anti-cancer imidazoline, targets PI3K and mTOR.</p>Fórmula:C22H23N5OForma y color:SolidPeso molecular:373.45DIF-3
CAS:<p>DIF-3 activates GSK-3β, degrades cyclin D1/c-Myc, and inhibits Wnt/β-catenin in DLD-1 cells, curbing HeLa cell proliferation.</p>Fórmula:C13H17ClO4Pureza:99.57%Forma y color:SolidPeso molecular:272.72EHT 1610
CAS:<p>EHT 1610 (EHT 5372) is a potent inhibitor of DYRK, with an IC50 of 0.36 nM and 0.59 nM for DYRK1A and DYRK1B, respectively.</p>Fórmula:C18H14FN5O2SPureza:98.59%Forma y color:SolidPeso molecular:383.4
